Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma

Lingling Du, Melissa DeFoe, Marianna B. Ruzinova, Jeffrey R. Olsen, Andrea Wang-Gillam

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


It is estimated that 10% to 20% of patients with pancreatic cancer present with resectable disease. Although surgery offers curative intent, the median survival after curative resection is less than 2 years. To improve clinical outcomes in this patient population, clinical studies have investigated the role of perioperative therapy, including neoadjuvant and adjuvant treatment in resectable pancreatic cancer. The role of adjuvant therapy has been well established by large randomized phase III studies, whereas benefit of the neoadjuvant approach remains inconclusive. Here, we review various treatment modalities and their clinical benefits in resectable pancreatic cancer.

Original languageEnglish
Pages (from-to)717-726
Number of pages10
JournalHematology/Oncology Clinics of North America
Issue number4
StatePublished - Aug 1 2015


  • Adjuvant therapy
  • HENT1
  • Neoadjuvant therapy
  • Predictive biomarkers
  • Resectable pancreatic cancer


Dive into the research topics of 'Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma'. Together they form a unique fingerprint.

Cite this